GeneBiology develops a patented new drug for serious diseases using the 505(b)(2) regulatory pathway. The 505(b)(2) pathway is the fastest, least expensive, and lowest risk regulatory pathway for the development of important new drugs, because both data on file for prior approval(s) and published data can be used to fulfill regulatory requirements for both clinical development and commercial approval, thereby substantially reducing the costs (in time and money) and the risks of developing new drugs. They combine deep expertise in medicine, drug development, and formulation chemistry to identify, develop, and market patented new formulations/new routes of administration/new indications for approved medicines.GeneBiology is a privately funded corporation that began operations in 2006 and intends to remain private.